Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The explanation is that commensal microbiome members within the gut of the mice might produce TLR agonists, thus promoting the rise of an oxidative stress milieu and tumor cell death.”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [165]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
An automated method for finding molecular complexes in large protein interaction networks
Bader, G. D., & Hogue, C. W. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-2 · Cited by 6,072
Cytoscape 2.8: new features for data integration and network visualization
Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L., & Ideker, T. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btq675 · Cited by 4,830
The impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Cited by
Items 201–258 of 258
Precision medicine using microbiota
Jobin, C. (2018) · Science · doi:10.1126/science.aar2946 · Cited by 133
Lang, T., Zhu, R., Zhu, X., Yan, W., Li, Y., Zhai, Y., Wu, T., Huang, X., Yin, Q., & Li, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-40439-y · Cited by 133
Gut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Self-citationSporadic colorectal cancer: microbial contributors to disease prevention, development and therapy
Drewes, J. L., Housseau, F., & Sears, C. L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.189 · Cited by 121
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Negi, S., Pahari, S., Bashir, H., & Agrewala, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01142 · Cited by 116
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Deng, X., Li, Z., Li, G., Li, B., Jin, X., & Lyu, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01607 · Cited by 114
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Pröbstel, A.-K., & Baranzini, S. E. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0587-y · Cited by 110
An intact gut microbiome protects genetically predisposed mice against leukemia
Vicente-Dueñas, C., Janssen, S., Oldenburg, M., Auer, F., González-Herrero, I., Casado-García, A., Isidro-Hernández, M., Raboso-Gallego, J., Westhoff, P., Pandyra, A. A., et al. (2020) · Blood · doi:10.1182/blood.2019004381 · Cited by 106
Butyrate production from high-fiber diet protects against lymphoma tumor
Wei, W., Sun, W., Yu, S., Yang, Y., & Ai, L. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1144879 · Cited by 102
“by modulating myeloid-derived cell functions in the tumor microenvironment.[10] Cyclophosphamide alters the composition of microbiota, which then modulate the anticancer immune effects of cyclophosphamide.”
BackgroundFrom the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation
Bajic, J. E., Johnston, I. N., Howarth, G. S., & Hutchinson, M. R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00104 · Cited by 100
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers
de Oliveira, G. A., Cheng, R. Y. S., Ridnour, L. A., Basudhar, D., Somasundaram, V., McVicar, D. W., Monteiro, H. P., & Wink, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6850 · Cited by 91
“Furthermore, commensal microbiota can modulate the tumor response by altering the levels of cytokine (TNF) production by myeloid cells within the tumor (68).”
BackgroundMelanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citation(2015) · PubMed · Cited by 86
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81
Self-citationThe European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“This has been shown to have a significant impact on the clinical course of allogeneic stem cell transplant recipients, but potentially also on the general interaction between host and tumor cells.(333,334) There is a need to better understand the pathogenesis and background of fever and infections in patients undergoi…”
BackgroundTerrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004191 · Cited by 80
Routy, B., Letendre, C., Enot, D., Chénard-Poirier, M., Mehraj, V., Séguin, N. C., Guenda, K., Gagnon, K., Woerther, P.-L., Ghez, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1258506 · Cited by 75
“The gut microbiota may also contribute to the therapeutic response to chemotherapy by mechanisms, which involve bacterial translocation, inflammation, and adaptive immunity.(11,12)”
BackgroundA dynamic atlas of immunocyte migration from the gut
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D., & Benoist, C. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi0672 · Cited by 74
Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Probiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Considerations for successful cancer immunotherapy in aged hosts
Hurez, V, Padrón, Á. S., Svatek, R. S., & Curiel, T. J. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12875 · Cited by 65
Di Luccia, B., Molgora, M., Khantakova, D., Jaeger, N., Chang, H.-W., Czepielewski, R. S., Helmink, B. A., Onufer, E. J., Fachi, J. L., Bhattarai, B., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi5374 · Cited by 59
“Human studies found associations between the gut microbiota and effectiveness of CPIs in patients with cancer ( 10 – 12 , 14 ) Here, we found that the enhanced responsiveness of tumors to anti–PD-1 in TREM2-deficient mice is dependent on the microbiota.”
BackgroundLiu, T., Wu, Y., Wang, L., Pang, X., Zhao, L., Yuan, H., & Zhang, C. (2019) · mBio · doi:10.1128/mbio.02903-18 · Cited by 56
Peric, Z., Botti, S., Stringer, J., Krawczyk, J., van der Werf, S., van Biezen, A., Aljurf, M., Murray, J., Liptrott, S., Greenfield, D. M., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0137-1 · Cited by 54
The role of the gut microbiome in colorectal cancer: Where are we? Where are we going?
Wieczorska, K., Stolarek, M., & Stec, R. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.07.006 · Cited by 50
Harness the functions of gut microbiome in tumorigenesis for cancer treatment
Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
Self-citationThe intestinal microbiome influences checkpoint blockade
Sears, C. L., & Pardoll, D. M. (2018) · Nature Medicine · doi:10.1038/nm.4511 · Cited by 43
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
Jenkins, S. V., Robeson, M. S., Griffin, R. J., Quick, C. M., Siegel, E. R., Cannon, M. J., Vang, K. B., & Dings, R. P. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4108 · Cited by 41
Non-Melanoma Skin Cancer: news from microbiota research
Squarzanti, D. F., Zavattaro, E., Pizzimenti, S., Amoruso, A., Savoia, P., & Azzimonti, B. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1794792 · Cited by 40
Cross-reactivity between microbial and tumor antigens
Zitvogel, L., & Kroemer, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102171 · Cited by 40
Sepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Baiden-Amissah, R. E. M., & Tuyaerts, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143586 · Cited by 30
Tumor-resident microbes: the new kids on the microenvironment block
Li, L., Chandra, V., & McAllister, F. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2023.12.002 · Cited by 30
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102125 · Cited by 29
Zhang, H., Hui, D., Li, Y., Xiong, G., & Fu, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01149 · Cited by 27
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., Richard, C., Iebba, V., Tidjani Alou, M., Becharef, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00684-w · Cited by 24
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes
Fessler, J. L., & Gajewski, T. F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0864 · Cited by 24
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Self-citationHow does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“Finally, Iida et al.(31) suggested that the adaptive immune system is secondary to the innate immune system, as they found that gut microbes enhance anticancer therapies through tumor necrosis factor and Toll-like receptor 4 signaling (although they were using an immunotherapy different to ICB).”
BackgroundInfluentialKatayama, Y., Yamada, T., Tanimura, K., Yoshimura, A., Takeda, T., Chihara, Y., Tamiya, N., Kaneko, Y., Uchino, J., & Takayama, K. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12969 · Cited by 20
The role of microbiota in allogeneic hematopoietic stem cell transplantation
Chang, C.-C., Hayase, E., & Jenq, R. R. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1872541 · Cited by 20
“SCFAs can further shape the cytokine profiles and drive colonic regulatory T cells (Tregs) differentiation [60,99].”
BackgroundInfluentialMicrobiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Unlocking the power of the microbiome for successful cancer immunotherapy
Clavijo-Salomon, M. A., & Trinchieri, G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011281 · Cited by 18
Self-citationThe Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
Mizobuchi, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110583 · Cited by 11
“demonstrated that OAL restores TNF expression and TNF-producing leukocytes in tumors (21).”
BackgroundHarnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers
Goc, J., & Sonnenberg, G. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0164 · Cited by 8
(2023) · doi:10.1158/0008-5472.c.6513535.v1
Supplementary Data from Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
(2023) · doi:10.1158/2159-8290.22540051.v1
Metadata
- Authors
- Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., Dai, R.-M., Kiu, H., Cardone, M., Naik, S., Patri, A. K., Wang, E., Marincola, F. M., Frank, K. M., Belkaid, Y., Trinchieri, G., & Goldszmid, R. S.
- Affiliations
- National Cancer Institute (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Institutes of Health (US)
- Technical Resources International (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- Corresponding author
- Iida, Noriho
- Dzutsev, Amiran
- Stewart, C. Andrew
- Trinchieri, Giorgio
- Goldszmid, Romina S.
- ORCID
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 967-970
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6709532
- OpenAlex
- W2124632458
- Cited by
- 2,251
- References
- 36
- Citations by year
- 2026: 100 · 2025: 184 · 2024: 214 · 2023: 251 · 2022: 295 · 2021: 248 · 2020: 247 · 2019: 173 · 2018: 151 · 2017: 124 · 2016: 96 · 2015: 91 · 2014: 71 · 2013: 4
- FWCI
- 38.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010793, ZIABC011153)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- gut microbiota, commensal bacteria, tumor microenvironment, cancer immunotherapy, platinum-based chemotherapy, myeloid-derived cells, inflammation, germ-free mice, antibiotic therapy, reactive oxygen species, cytokine production, tumor necrosis, tumor-infiltrating immune cells
- MeSH terms
- Oxaliplatin, Animals, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Gene Expression Regulation, Germ-Free Life, Immunotherapy, Inflammation, Intestines, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasm Transplantation, Neoplasms, Oligodeoxyribonucleotides, Organoplatinum Compounds, Phagocytosis, Symbiosis, Tumor Necrosis Factor-alpha, Down-Regulation, Reactive Oxygen Species, Antigen Presentation, Bacterial Physiological Phenomena, Mice, Tumor Microenvironment, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.